Opportunity Information: Apply for RFA NS 09 003
Apply for RFA NS 09 003
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Optimization of Small Molecule Probes for the Nervous System (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273 Alcohol Research Programs 93.279 Drug Abuse and Addiction Research Programs 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders.
- This funding opportunity was created on Dec 31, 2008 and posted on Dec 30, 2008.
- Applicants must submit their applications by Mar 3, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Small businesses Special district governments Independent school districts County governments City or township governments Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments For profit organizations other than small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity "Optimization of Small Molecule Probes for the Nervous System (R21)" (Funding Opportunity Number RFA-NS-09-003) was a discretionary research grant announcement led by the National Institute of Neurological Disorders and Stroke (NINDS), with participation from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA). Its core goal was to speed the creation of high-quality small molecule research probes that can be used to study biological function in the nervous system. Rather than funding early, exploratory target discovery or the initial screening itself, the emphasis was on the next step: taking already-identified hit compounds and pushing them through advanced medicinal chemistry and fit-for-purpose biological testing so they become strong, reliable tools for neuroscience research.
The opportunity targeted projects where investigators had already screened small molecule collections using in vitro biological assays and could show a credible relationship between chemical structure and biological activity. In practice, that means applicants were expected to come in with one or more probe candidates that were not just "active," but also supported by early structure-activity relationship (SAR) signals (for example, analogs or related compounds showing activity trends, or chemical features that plausibly explain potency). The FOA asked applicants to nominate probe candidates from distinct structural series, then carry out iterative analogue design, synthesis or acquisition, and repeated testing to build SAR and improve key performance characteristics. The work was expected to be run using in vitro assays adapted to medium-throughput needs, reflecting that SAR campaigns can require evaluating many analogs efficiently while still collecting decision-quality data.
The intended outcome was a refined small molecule probe suitable for future pharmacological studies proposed by the investigator. The FOA specifically highlighted attributes such as affinity, selectivity, and activity, which are central to whether a compound is usable as a probe rather than merely a screening hit. In other words, the funded research was meant to produce compounds that can interrogate a biological target or pathway in nervous system research with enough potency and selectivity to generate interpretable results, and with sufficient supporting data to justify downstream use in more advanced experiments.
A notable expectation was the use of publicly available cheminformatic resources to help acquire compounds and support semi-custom synthesis of analogues. This reflects an intent to leverage existing public infrastructure and tools for chemical exploration, reduce redundancy, and make the medicinal chemistry phase more efficient. The announcement frames semi-custom synthesis of analogues as required for these studies, reinforcing that the central activity is medicinal chemistry optimization paired with biological testing, not simply purchasing a few catalog compounds and running limited assays.
From an administrative standpoint, the program used the NIH R21 activity code, which is typically aimed at exploratory and developmental research that can generate strong proof-of-concept data and enable larger follow-on studies. The FOA was posted December 30, 2008, with an application due date of March 3, 2009, and it was later archived on April 2, 2009. Cost sharing was not required. The award ceiling was listed as 0, which generally indicates that applicants should consult the full FOA for budget guidance rather than relying on a fixed cap in the summary listing.
Eligibility was broad and included many organization types that commonly apply for NIH research funding, such as public and private institutions of higher education, nonprofits (including both 501(c)(3) and certain non-501(c)(3) entities), small businesses, and various government entities (state, county, city or township), as well as eligible tribal governments and tribal organizations. The participating NIH institutes and the CFDA listings tied to this opportunity reflect its cross-cutting relevance to neurological disorders (93.853), alcohol research (93.273), and drug abuse and addiction research (93.279), consistent with the shared interest in tools that can probe nervous system biology in contexts relevant to brain function, addiction, and neuro-related disease mechanisms.
Overall, this FOA was designed to fill a specific gap between discovery screening and downstream biological application: it supported the focused optimization work needed to convert early hits into dependable, selective, and potent small molecule probes, backed by iterative SAR and medium-throughput in vitro testing, so the resulting compounds could be used as practical tools in future neuroscience pharmacology studies.
FAQs: Optimization of Small Molecule Probes for the Nervous System (R21) (RFA-NS-09-003)
What is the name of this NIH funding opportunity?
The funding opportunity is titled "Optimization of Small Molecule Probes for the Nervous System (R21)".
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is RFA-NS-09-003.
Which NIH institute led this program?
The announcement was led by the National Institute of Neurological Disorders and Stroke (NINDS).
Which NIH institutes participated?
In addition to NINDS, participating institutes included the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA).
What was the core goal of this funding opportunity?
The core goal was to speed the creation of high-quality small molecule research probes that can be used to study biological function in the nervous system.
What kind of research did this FOA emphasize?
This FOA emphasized the optimization stage: taking already-identified hit compounds and advancing them through medicinal chemistry optimization and fit-for-purpose biological testing to create reliable neuroscience research probes.
What activities were explicitly not the main focus of the FOA?
The emphasis was not on early, exploratory target discovery or the initial screening itself. Instead, the focus was on improving and validating compounds that had already been identified as hits.
What did applicants need to have in hand before applying?
Applicants were expected to have already screened small molecule collections using in vitro biological assays and to be able to show a credible relationship between chemical structure and biological activity (early SAR evidence).
What does "credible SAR" mean in the context of this FOA?
It means applicants should be able to point to early signals that connect structure to activity, such as active analogs, activity trends across related compounds, or chemical features that plausibly explain potency or other performance characteristics.
Were applicants expected to propose more than one chemical series?
Yes. The FOA asked applicants to nominate probe candidates from distinct structural series, then run iterative optimization to build SAR and improve probe performance.
What was the expected workflow supported by this grant?
The expected workflow included iterative analogue design, synthesis or acquisition of analogues, and repeated biological testing to strengthen SAR and improve key probe attributes.
What type of assays were expected for testing analogues?
The work was expected to use in vitro assays adapted to medium-throughput needs, reflecting that SAR campaigns often require testing many analogs efficiently while still generating decision-quality data.
What was the intended end product of the funded work?
The intended outcome was a refined small molecule probe that would be suitable for future pharmacological studies proposed by the investigator.
Which probe attributes did the FOA highlight as important?
The FOA specifically highlighted affinity, selectivity, and activity as key attributes that determine whether a compound can function as a usable research probe rather than merely a screening hit.
Why was selectivity emphasized?
Selectivity was emphasized because the goal was to produce probes that can interrogate a biological target or pathway with enough specificity to generate interpretable results and justify downstream use in more advanced experiments.
What role did medicinal chemistry play in this FOA?
Medicinal chemistry optimization was central. The FOA reinforced that the work should involve semi-custom synthesis of analogues paired with biological testing, rather than limited evaluation of a small number of off-the-shelf catalog compounds.
Were applicants expected to use public cheminformatics resources?
Yes. A notable expectation was the use of publicly available cheminformatic resources to help acquire compounds and to support semi-custom synthesis of analogues, to leverage public infrastructure and reduce redundancy.
What NIH grant mechanism (activity code) was used?
The program used the NIH R21 activity code, typically intended for exploratory and developmental research that can generate proof-of-concept data and enable follow-on studies.
When was the FOA posted?
The FOA was posted on December 30, 2008.
What was the application due date?
The application due date was March 3, 2009.
What is the status of this FOA now?
The FOA was later archived on April 2, 2009.
Was cost sharing required?
No. Cost sharing was not required.
Was there a fixed award budget cap?
The award ceiling was listed as 0, which generally indicates applicants should consult the full FOA for budget guidance rather than relying on a fixed cap in the summary listing.
Who was eligible to apply?
Eligibility was broad and included many organization types, including public and private institutions of higher education, nonprofits (including 501(c)(3) and certain non-501(c)(3) entities), small businesses, and government entities (state, county, city, or township), as well as eligible tribal governments and tribal organizations.
Which CFDA program areas were associated with this opportunity?
The CFDA listings reflected cross-cutting relevance to: 93.853 (neurological disorders), 93.273 (alcohol research), and 93.279 (drug abuse and addiction research).
How did the participating institutes relate to the scientific scope?
The participating institutes and CFDA areas aligned with shared interest in tools that can probe nervous system biology in contexts relevant to brain function, addiction, and neurological disease mechanisms.
What gap in the research pipeline was this FOA designed to fill?
It was designed to bridge the gap between discovery screening and downstream biological application by funding the focused optimization needed to convert early hits into dependable probes supported by iterative SAR and medium-throughput in vitro testing.
Browse more opportunities from the same category: Health
Next opportunity: Career Development Award to Promote Diversity in Neuroscience Research (K01)
Previous opportunity: Office of Elementary and Secondary Education Overview Information College Assistance Migrant Program (CAMP) CFDA 84.149A
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA NS 09 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA NS 09 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Career Development Award to Promote Diversity in Neuroscience Research (K01) Apply for PAR 09 065 Funding Number: PAR 09 065 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Partnerships for Complementary Alternative Medicine (CAM) Clinical Translational Research (PCCTR) (U19) Apply for PAR 09 066 Funding Number: PAR 09 066 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINR Career Transition Award (K22) Apply for PAR 09 067 Funding Number: PAR 09 067 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Research Scholar Development Award (K22) Apply for PAR 09 068 Funding Number: PAR 09 068 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Quick Trials for Imaging and Image Guided Interventions Exploratory Grants (R21) Apply for PAR 08 147 Funding Number: PAR 08 147 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Data Coordinating Center for Autism and Other Developmental Disabilities Research and Epidemiologic Studies (U10) Apply for RFA DD 09 002 Funding Number: RFA DD 09 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $700,000 |
| NCI Transition Career Development Award to Promote Diversity (K22) Apply for PAR 09 069 Funding Number: PAR 09 069 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| TransACTION Prevention and Care Services for At Risk Mobile Populations Apply for 663 A 09 006 Funding Number: 663 A 09 006 Agency: Ethiopia USAID Addis Ababa Category: Health Funding Amount: $40,000,000 |
| AHRQ Health Services Research Projects (R01) Apply for PA 09 070 Funding Number: PA 09 070 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| AHRQ Health Services Research Demonstration and Dissemination Grants (R18) Apply for PA 09 071 Funding Number: PA 09 071 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Chiropractic Demonstration Projects Apply for HRSA 09 108 Funding Number: HRSA 09 108 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Grants to States to Support Oral Health Workforce Activities Apply for HRSA 09 109 Funding Number: HRSA 09 109 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Clinical Interventions to Increase Organ Procurement Apply for HRSA 09 173 Funding Number: HRSA 09 173 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Part D Coordinated HIV Services and Access to Research for Women, Infant, Children and Youth Apply for HRSA 09 202 Funding Number: HRSA 09 202 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Licensure Portability Grant Program Apply for HRSA 09 196 Funding Number: HRSA 09 196 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Collaborative Study of Suicidality and Mental Health in the U.S. Army (U01) Apply for RFA MH 09 140 Funding Number: RFA MH 09 140 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Service Expansion for Enabling Services for Special Populations Apply for HRSA 09 190 Funding Number: HRSA 09 190 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| International Research in Infectious Diseases including AIDS (IRIDA) Program (R01) Apply for PAR 08 130 Funding Number: PAR 08 130 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Electronic Health Record Implementation Initiative Apply for HRSA 09 198 Funding Number: HRSA 09 198 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| The Bernard Osher Foundation/NCCAM CAM Practitioner Research Career Development Award (K01) Apply for PAR 09 072 Funding Number: PAR 09 072 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA NS 09 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.